CAHG establishes one 'seamless' shop

Share this article:
The Omnicom company formerly known as Corbett Accel Healthcare Group has devolved from a network into an agency, folding all of its once-independent agencies into one shop under the CAHG umbrella.
The shop said it was seeking to fulfill client expectations for a “seamless agency.” CAHG brands subsumed under the new identity include flagship full-service shop Corbett, promotional med ed shop Accel, clinical trials enrollment firm Iris, e-CRM and digital shop Kinect and launch agency Surge, as well as genomic science unit Potentia. LinQ will continue as an independent entity “to support CAHG and its clients through deployment of technology-inspired studio solutions.”
As part of the reorganization, the network named seven partners: former chief talent officer Phila Broich; Elaine Eisen, formerly president of Corbett Worldwide Healthcare Communications; ex-strategic planning and new ventures head Suri Harris; former CFO Dennis Hoppe; former Surge president Carleen Kelly; former LinQ managing director Tony Morello; and ex-chief creative officer Robin Shapiro. All will report to CEO Scott Cotherman.
“The new integrated structure takes advantage of the firm's dominant presence in New York and Chicago, the two most important markets for healthcare marketing communications talent in the US,” the firm said in a statement. “CAHG's clients expect the agency to custom-configure teams from across geographies, assembling the best talent in service to their brands and customer markets. CAHG's new, seamless agency approach makes this more of a reality than ever before.”
Share this article:

Email Newsletters

More in Features

Leadership Exchange: How Do We Get Beyond the Pill?

Leadership Exchange: How Do We Get Beyond the ...

As its focus moves from manufacturing to service, pharma needs to partner with healthcare neophytes as well as established players. James Chase asks six experts to assess the risks and ...

FDA and off-label uses: a balancing act

FDA and off-label uses: a balancing act

FDA's current re-examination of its off-label promotion policies in light of the First Amendment is a delicate balancing act between its rock-solid traditional enforcement posture and a diverse new electronic ...

Read the complete August 2014 Digital Edition

Read the complete August 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.